Expert conversations.
On your schedule.

The Anti-Kickback Statute (AKS) requires careful consideration in the context of pharmaceutical-sponsored testing programs, as confirmed by recent DOJ settlements. Maintaining a compliant firewall between sponsored testing and commercial sales is non-negotiable.

This webinar, featured a detailed regulatory analysis from McDonald Hopkins and practical real-world data (RWD) solutions from Prognos Health, which can equip compliance, legal, and commercial teams with the essential elements required to establish a compliant roadmap. We reviewed the key factors from relevant OIG Advisory Opinions and highlighted "red flags" cited in enforcement actions. Prognos demonstrated how utilizing sophisticated Real-World Data tools can support the necessary data separation and attenuation required to mitigate legal and regulatory risk.

Genetic testing has enabled faster and more precise identification of patients who could benefit from new and existing treatments. With robust genomic data, biopharmaceutical companies can better understand the genetic prevalence of rare diseases and collaborate with healthcare providers to increase access to therapeutic options for their patients. Prognos Health and Labcorp, now including Invitae, are jointly committed to enabling life sciences teams to leverage genomic insights to support clinical development and commercialization of potentially life-saving therapies for rare disease patients.

Watch to hear more about:

• Advanced solutions that enable pharma to help rare disease patients gain access to potential treatment options
• Benefits of combining genetic and non-genetic clinical data to create deterministic, probabilistic and predictive profiles
• Challenges and advances around access to diagnosis, treatment and monitoring of rare diseases

This session delves into critical questions such as:

• Privacy in RWD: Untangle genetic data vs. de-identified data for confident use of Real-World Data.
• Data Security: Safeguard genetic data with access controls and partner selection for patient privacy.
• De-identification Techniques: Learn robust methods to anonymize patient data in RWD use.

This on-demand session will equip you with valuable knowledge on:

• The growing adoption of liquid biopsies and their impact on patient diagnosis.
• How life science companies can leverage liquid biopsy data to create more effective HCP engagement strategies.
• Identifying scenarios where liquid biopsies offer a clearer picture than traditional tissue biopsies.

Check out this recorded webinar to hear more about Advancements in Comprehensive Genomic Profiling (CGP) and Next Generation Sequencing (NGS) that are driving personalized medicine and the adoption of targeted therapies for individual patients in cancer care today. This technology helps medical professionals better understand their patient’s tumors, discover actionable biomarkers, and make the right clinical decision for the right patient.